ALFA Finder
India's fastest NSE & BSE filing alerts on Telegram, filtered to the stocks you hold
Telegram alerts
alfafinder.com →
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
39 announcements with these filters
Chandan Healthcare filed Crisil's monitoring report on warrant issue proceeds for the quarter ended September 30, 2026. Utilisation matched the stated objects with no deviation or delay.
Chandan Healthcare calls an EGM on 20 November 2026 to approve related party transactions, including director guarantees. E-voting runs 17 to 19 November 2026.
Chandan Healthcare's Q2 FY2027 revenue from diagnostics grew 46.66% YoY to Rs. 56.38 Crore, while its franchise network expanded to 685 locations.
Chandan Healthcare Limited secured a ₹5.22 Crore medical equipment loan from ICICI Bank for purchasing a 128-slice CT scanner.
Mr. Vinod Jain has resigned from his position as Independent Director of Chandan Healthcare Limited, effective October 5, 2026, due to other professional commitments.
Chandan Healthcare Limited held its 23rd Annual General Meeting on September 30, 2026. The meeting covered routine business, including financial adoption and board appointments.
Chandan Healthcare allotted 6,50,000 equity shares upon conversion of warrants for ₹15.21 Crore consideration.
Chandan Healthcare scaled its diagnostic franchise network to 500+ centres, reaching a total of 568+ centres. It targets 1,000 centres by FY27-end and 3,000 in two years.
Chandan Healthcare clarified to NSE it has one reportable segment, explaining the omission of segment-wise details in its Q4 FY27 financial results.
Chandan Healthcare Limited has allotted 5,99,998 equity shares upon conversion of fully convertible warrants, aggregating to ₹14.04 Crore.
Chandan Healthcare Ltd's board approved the appointment of an Independent Director, ratified cost auditor remuneration, and recommended varying the objects for utilising unutilised warrant proceeds.
Chandan Healthcare Limited announced the EGM voting results held on 29 August 2026. Shareholders approved the disinvestment of its entire shareholding in Chandan Pharmacy Limited.
Chandan Healthcare Limited held an EGM to approve the disinvestment of its entire stake in subsidiary Chandan Pharmacy Limited for approximately ₹16.77 Crore. This strategic divestment focuses resources on core diagnostics.
Chandan Healthcare is pivoting from pharmacy trading to a high-margin diagnostic-led strategy. The company reported healthy revenue growth but is over-relying on capital-light franchise scaling to drive future profitability.
Chandan Healthcare reported strong Q1 FY27 results with 19.62% YoY revenue growth and 42.27% EBITDA growth, driven by expansion into 15 states and diversified B2C, B2B, and B2G segments.
Chandan Healthcare Ltd reported revenue from operations of ₹80.9 Cr (+19.1% YoY) and net profit of ₹7.5 Cr (+29.3% YoY) for Q1 FY27.
Chandan Healthcare Limited submitted the Monitoring Agency Report for the quarter ended June 30, 2026, regarding the utilization of proceeds from its preferential issue.
Chandan Healthcare Limited scheduled a board meeting for August 14, 2026. The meeting will consider unaudited financial results for the quarter ended June 30, 2026.
Chandan Healthcare Limited received an Administrative Warning Letter from SEBI regarding disclosure lapses in its Red Herring Prospectus. No monetary penalty was imposed.
Chandan Healthcare approved the divestment of its entire 53.56% stake in Chandan Pharmacy to group company Chandan Hospital. The transaction is valued at ₹31.31 Crore.
Chandan Healthcare Limited announced an EGM on August 29, 2026, to approve the sale of its entire 53.56% stake in Chandan Pharmacy Limited for Rs. 16.77 Crore.
Chandan Healthcare Limited scheduled an EGM for August 29, 2026. Shareholders will vote on disinvesting the entire stake in material subsidiary Chandan Pharmacy Limited.
Chandan Healthcare Limited will divest its 53.56% stake in subsidiary Chandan Pharmacy Limited for Rs.16.77 Crore. The sale is subject to shareholder approval at the upcoming EGM.
Chandan Healthcare Limited announced that Dayal Institute of Medical Sciences has withdrawn its complaints, resolving all disputes and claims between the parties amicably.
Chandan Healthcare Limited voluntarily submitted its Integrated Corporate Governance Report for the quarter ended June 30, 2026. This follows the company's proposed transition from the NSE SME platform to the Main Board.
Chandan Healthcare reported ₹48.67 Crore in quarterly operating sales, a 35.64% YoY increase. The company expanded its network by adding 140 new diagnostic centres.
Chandan Healthcare resubmitted revised audited financial results for H1 and FY ended March 2026 per exchange clarification. The filing corrects prior submission issues and includes the auditor's report.
Chandan Healthcare Limited responded to NSE’s surveillance query, stating the share price movement is market‑driven with no undisclosed information. The company affirmed compliance with SEBI LODR regulations.
Chandan Healthcare reported strong FY26 performance with Revenue of ₹280.67 Cr and PAT of ₹27.06 Cr, driven by network expansion and strategic PPP projects.
Chandan Healthcare reported robust FY26 results with 20.43% revenue growth, transitioning to a pan-India diagnostic model while scaling franchise and PPP projects.